Through its three wholly-owned subsidiaries, Imagin Molecular Corporation owns and operates several positron emission tomography (PET) imaging centers across North America. The company’s main focal points are the business opportunities provided by the detection of disease in the brain and heart, and the diagnosis of some forms of cancer.
In simplified terms, PET imaging is the practice of injecting radioactive isotopes, or tracers, into a living subject for the purpose of constructing a three-dimensional map of potentially diseased tissues/organs. Upon introduction to the patient’s circulatory system, the radioisotopes begin to decay, emitting positrons, which are the antimatter counterparts of electrons. When an antimatter particle meets a particle of matter, the result is the annihilation of both molecules. This collision produces two photons, which radiate away from one another at 180 degrees, and are subsequently detected by a computer that calculates and maps their point of origin.
Imagin Molecular Corporation facilitates this diagnostic process for the Beth Israel Medical Center, with plans to expand its service to more than 5000 hospitals and independent cardiologists. Imagin has positioned itself to be a potentially major player in the field of molecular imaging. Heart disease claims the lives of over 650,000 people each year, many of whom could be saved in the event of early detection. It is in that capacity, that Imagin Molecular Corporation is working toward providing heart disease sufferers a greater chance of survival.
Let us hear your thoughts below:
